Bio-Path Holdings Inc. (NASDAQ: BPTH) is developing targeted DNA therapeutics for blood cancers and solid tumors.

Bio-Path Holdings (NASDAQ: BPTH) is a clinical stage biotechnology company developing therapeutics for the treatment of cancer and systemic diseases. Bio-Path's RNAi technology for drug development, DNAbilize™, uses a novel liposomal antisense DNA platform that allows for systemic delivery of nucleic acids without toxicity. Using DNAbilize™ clinicians can inhibit the production of proteins involved in cancer and block pathways involved in disease progression.  

Bio-Path is located in Houston in proximity to the Texas Medical Center and has a close working relationship with The MD Anderson Cancer Center.  Bio-Path is currently in Phase II trials for acute myeloid leukemia for their lead drug candidate, prexigebersen, in combination with the frontline treatment for elderly and fragile patients. Bio-Path expects to begin the safety segment of the Phase II trial for blast phase and accelerated phase chronic myeloid leukemia in combination with the frontline treatment in 2017. Work is ongoing for treatment of solid tumors and new protein targets in cancer to address additional high need areas in oncology and autoimmune disease.

COMPANY HIGHLIGHTS

  • Proprietary antisense and liposome delivery technology breakthrough for DNA drugs, potentially solving the challenges of delivering these molecules directly to target cells without side effects
  • Original technology licensed from The MD Anderson Cancer Center. Company maintains strong relationship with the Cancer Center
  • Strong IP position with composition of matter and method patents for antisense targets and manufacturing
  • Lead product candidate, prexigebersen (Liposomal Grb2) formerly BP1001, in the clinic for blood cancers and in development for solid tumors. Second product candidate, BP1002 (Liposomal Bcl2) is IND-ready
  • Promising clinical data for BP1001 shows that the drug has been well tolerated with possible anti-leukemic effects, including patients stabilizing for extended treatment

Research Coverage

Maxim Group - Jason Kolbert

H.C. Wainwright - Yi Chen

Recent Events

DON'T SEE YOUR CITY?